Jain PharmaBiotech, Feb 2012, Pages: 485
RNAs that are used in a sequence-specific manner to recognize and destroy complementary RNA. The report compares RNAi with other antisense approaches using oligonucleotides, aptamers, ribozymes, peptide nucleic acid
Takeda Pacific, July 2007, Pages: 131
the market landscape and analyzes the players. The market areas studied range from life science research products and services to therapeutics or drug delivery tools for RNAi agents.
The report discusses RNAi topics
Business Insights, Sep 2008, Pages: 253
in this report."
RNA interference continues to offer significant promise for a host of therapeutic treatments. Potentially any disease-causing gene, cell type or tissue can be targeted with RNAi, including those
RNCOS E-Services Private Limited, June 2011, Pages: 65
by the advancement of RNAi-based therapeutics for multiple indications in future.
Our report identifies that, at the segment level, Nanoparticle RNAi delivery holds the maximum share in the global market. However
Business Insights, June 2007, Pages: 244
also been made in the development of RNAi-based therapeutic products, bringing them significantly closer to the market.
‘Outlook for RNAi 2007’ is a new report which provides a detailed insight
TriMark Publications, Dec 2008, Pages: 147
knockdown. This field has rapidly emerged as a fast-growing new market.
The purpose of this report is to review the market for RNAi testing equipment and supplies. RNAi is a mechanism in molecular biology
Decision Resources, Inc., Jan 2008, Pages: 26
companies. The success of RNAitherapeutics rests on the development of technologies that can deliver these agents to their targets.
Questions Answered in This Report:
- Several companies are focusing
Fuji-Keizai USA, Inc., Feb 2006, Pages: 130
growing new market. Much like the go-go times of 1999, VC investments in 2003-2005 have produced a growing new crop of interesting RNAi companies.
This report assesses this emerging commercial
La Merie, March 2011, Pages: 67
, aptamer, LNA RNA, RNAi and CpG oligonucleotide therapeutics for treatment of a variety of clinical disorders. In addition, the report lists company-specific R&D pipelines of RNA Therapeutics in Clinical
Business Insights, May 2005
%.
"The Outlook for RNAi: Accelerating Drug Discovery and the Development of RNAiTherapeutics" is a new management report which analyzes the latest trends in the RNAi market, allowing pharmaceutical companies
Jain PharmaBiotech, Feb 2012, Pages: 481
This report reviews the current state-of-art of antiviral approaches including vaccines, pharmaceuticals and innovative technologies for delivery of therapeutics. The introduction starts
Business Insights, April 2005, Pages: 186
Findings of the Report:
- The markets for LOC devices, nanotechnology, and RNAi technologies and therapeutics are set to experience phenomenal growth rates, driven
by novel product developments and new
Decision Resources, Inc., Aug 2005, Pages: 19
the expression of deleterious genes. RNA-based therapeutics are a relatively new addition to the field, and we focus on three such technologies in this report: antisense oligonucleotides, RNA interference
Jain PharmaBiotech, Feb 2012, Pages: 348
This report describes and evaluates animal biotechnology and its application in veterinary medicine and pharmaceuticals as well as improvement in food production. Knowledge of animal genetics
Decision Resources, Inc., Feb 2010, Pages: 32
targets, but companies are also investigating novel targets such as viral maturation.
Questions Answered in This Report
- Although no HCV-specific antiviral agents have reached the market, the HCV
La Merie, May 2010, Pages: 26
The present Competitive Intelligence Report about RSV Vaccines & Therapeutics provides a competitor evaluation in the field of prophylactic vaccines and therapeutic antibodies, small molecules
GBI Research, Feb 2010, Pages: 89
and the promising drugs. The study elucidates the current competitive landscape of the RNA therapeutics market. Finally, the report deals with key trend analysis on mergers and acquisitions, and licensing agreements
Jain PharmaBiotech, Feb 2012, Pages: 659
the therapeutic applications. This report takes broad overview of gene therapy and is the most up-to-date presentation from the author on this topic built-up from a series of gene therapy report written by him
